{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:22:35Z","timestamp":1769574155062,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","award":["240096"],"award-info":[{"award-number":["240096"]}],"id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Thyroid cancer is a very damaging disease. The most common treatment for this disease includes thyroidectomy and then using radioactive iodine (RAI). RAI has many side effects, including a decrease in salivary secretions, followed by dry mouth and oral and dental injuries, as well as increased inflammation and oxidative stress. Selenium can be effective in these patients by improving inflammation and oxidative stress and by modulating salivary secretions. So far, only one clinical trial has investigated the effect of selenium on thyroid cancer patients treated with radioiodine therapy (RIT) conducted on 16 patients; considering the importance of this issue, to show the potential efficacy of selenium in these patients, more high-quality trials with a larger sample size are warranted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a parallel double-blind randomized controlled clinical trial that includes 60 patients aged 20 to 65\u00a0years with papillary thyroid cancer (PTC) treated with RAI and will be conducted in Seyyed al-Shohada Center, an academic center for referral of patients to receive iodine, Isfahan, Iran. Thirty patients will receive 200\u00a0\u00b5g of selenium for 10\u00a0days (3\u00a0days before to 6\u00a0days after RAI treatment) and another 30 patients will receive a placebo for the same period. Sonographic findings of major salivary glands, salivary secretions, and sense of taste will be evaluated before and 6\u00a0months after 10-day supplementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Due to its anti-inflammatory and antioxidant effects, as well as improving salivary secretions, selenium may improve the symptoms of thyroid cancer treated with radioactive iodine. In past studies, selenium consumption has not reduced the therapeutic effects of radiation therapy, and at a dose of 300 to 500\u00a0\u03bcg\/day, it has not had any significant side effects in many types of cancer under radiation therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Iranian Registry of Clinical Trials <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.irct.ir\/trial\/58522\">IRCT20201129049534N6<\/jats:ext-link>. Registered on 16 September 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07470-2","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T07:02:14Z","timestamp":1691391734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Sepide","family":"Amini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Golshani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somayeh","family":"Hajiahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Askari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijan","family":"Iraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-6129","authenticated-orcid":false,"given":"Mohammad","family":"Bagherniya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"7470_CR1","doi-asserted-by":"crossref","unstructured":"Bikas A, Burman KD. Epidemiology of thyroid cancer. Springer; 2019. p. 541\u20137.","DOI":"10.1007\/978-3-319-72102-6_35"},{"issue":"5","key":"7470_CR2","first-page":"1191-","volume":"18","author":"E Younis","year":"2017","unstructured":"Younis E. Oncogenesis of thyroid cancer. Asian Pacific J Cancer Prev. 2017;18(5):1191-.","journal-title":"Asian Pacific J Cancer Prev"},{"key":"7470_CR3","doi-asserted-by":"crossref","first-page":"102-","DOI":"10.3389\/fendo.2020.00102","volume":"11","author":"A Prete","year":"2020","unstructured":"Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol. 2020;11:102-.","journal-title":"Front Endocrinol"},{"issue":"1","key":"7470_CR4","first-page":"1045-","volume":"3","author":"H Katoh","year":"2015","unstructured":"Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and general considerations of thyroid cancer. Ann Clin Pathol. 2015;3(1):1045-.","journal-title":"Ann Clin Pathol"},{"issue":"1","key":"7470_CR5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41574-019-0263-x","volume":"16","author":"J Kim","year":"2020","unstructured":"Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16(1):17\u201329.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"7470_CR6","doi-asserted-by":"crossref","first-page":"1185-","DOI":"10.3390\/ijerph16071185","volume":"16","author":"M Fiore","year":"2019","unstructured":"Fiore M, Oliveri Conti G, Caltabiano R, Buffone A, Zuccarello P, Cormaci L, et al. Role of emerging environmental risk factors in thyroid cancer: a brief review. Int J Environ Res Public Health. 2019;16(7):1185-.","journal-title":"Int J Environ Res Public Health"},{"key":"7470_CR7","doi-asserted-by":"crossref","first-page":"105085-","DOI":"10.1016\/j.oraloncology.2020.105085","volume":"112","author":"MR Youssef","year":"2021","unstructured":"Youssef MR, Reisner ASC, Attia AS, Hussein MH, Omar M, LaRussa A, et al. Obesity and the prevention of thyroid cancer: impact of body mass index and weight change on developing thyroid cancer\u2013Pooled results of 24 million cohorts. Oral Oncol. 2021;112:105085-.","journal-title":"Oral Oncol"},{"issue":"18","key":"7470_CR8","doi-asserted-by":"crossref","first-page":"4413-","DOI":"10.3390\/ijms20184413","volume":"20","author":"SM Ferrari","year":"2019","unstructured":"Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, et al. Immune and inflammatory cells in thyroid cancer microenvironment. Int J Mol Sci. 2019;20(18):4413-.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7470_CR9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2265.2009.03699.x","volume":"72","author":"M Muzza","year":"2010","unstructured":"Muzza M, Degl\u2019Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol. 2010;72(5):702\u20138.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"7470_CR10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mce.2009.10.003","volume":"321","author":"V Guarino","year":"2010","unstructured":"Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and inflammation. Mol Cell Endocrinol. 2010;321(1):94\u2013102.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"7470_CR11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","volume":"17","author":"M Schlumberger","year":"2021","unstructured":"Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17(3):176\u201388.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"7470_CR12","doi-asserted-by":"crossref","first-page":"10-","DOI":"10.3390\/ijms21010010","volume":"21","author":"OV Ancker","year":"2019","unstructured":"Ancker OV, Kr\u00fcger M, Wehland M, Infanger M, Grimm D. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci. 2019;21(1):10-.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7470_CR13","first-page":"30-","volume":"8","author":"QT Nguyen","year":"2015","unstructured":"Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA. Diagnosis and treatment of patients with thyroid cancer. American Health Drug Benefits. 2015;8(1):30-.","journal-title":"American Health Drug Benefits"},{"issue":"11","key":"7470_CR14","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/hed.26359","volume":"42","author":"MK Le Roux","year":"2020","unstructured":"Le Roux MK, Graillon N, Guyot L, Taieb D, Galli P, Godio-Raboutet Y, et al. Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: long-term study. Head Neck. 2020;42(11):3133\u201340.","journal-title":"Head Neck"},{"issue":"2","key":"7470_CR15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/00016357.2017.1399214","volume":"76","author":"FI Daniel","year":"2018","unstructured":"Daniel FI, Lima LD, Grando LJ, Castro R, Cordeiro EAK, Dos Santos CR. Salivary evaluation in radioactive I131 treated patients with thyroid carcinoma. Acta Odontol Scand. 2018;76(2):148\u201352.","journal-title":"Acta Odontol Scand"},{"issue":"6","key":"7470_CR16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.bjoms.2017.03.019","volume":"55","author":"E Moreddu","year":"2017","unstructured":"Moreddu E, Baumstarck-Barrau K, Gabriel S, Fakhry N, Sebag F, Mundler O, et al. Incidence of salivary side effects after radioiodine treatment using a new specifically-designed questionnaire. Br J Oral Maxillofac Surg. 2017;55(6):609\u201312.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"8","key":"7470_CR17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/MNM.0000000000000325","volume":"36","author":"J-q Wu","year":"2015","unstructured":"Wu J-q, Feng H-j, Ouyang W, Sun Y-g, Chen P, Wang J, et al. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up. Nuclear Med Commun. 2015;36(8):819\u201326.","journal-title":"Nuclear Med Commun"},{"issue":"5","key":"7470_CR18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/thy.2012.0050","volume":"23","author":"PW Rosario","year":"2013","unstructured":"Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013;23(5):617\u20139.","journal-title":"Thyroid"},{"issue":"10","key":"7470_CR19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2967\/jnumed.108.061382","volume":"50","author":"RK Grewal","year":"2009","unstructured":"Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009;50(10):1605\u201310.","journal-title":"J Nucl Med"},{"issue":"1","key":"7470_CR20","first-page":"ZC60","volume":"10","author":"RK BaDam","year":"2016","unstructured":"BaDam RK, Suram J, Babu DBG, Waghray S, Marshal R, Bontha SC, et al. Assessment of salivary gland function using salivary scintigraphy in pre and post radioactive iodine therapy in diagnosed thyroid carcinoma patients. J Clin Diagnostic Res. 2016;10(1):ZC60-ZC.","journal-title":"J Clin Diagnostic Res"},{"issue":"3","key":"7470_CR21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.clinimag.2014.12.018","volume":"39","author":"HN Lee","year":"2015","unstructured":"Lee HN, An JY, Lee KM, Kim EJ, Choi WS, Kim DY. Salivary gland dysfunction after radioactive iodine (I-131) therapy in patients following total thyroidectomy: emphasis on radioactive iodine therapy dose. Clin Imaging. 2015;39(3):396\u2013400.","journal-title":"Clin Imaging"},{"issue":"5","key":"7470_CR22","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0194599813479777","volume":"148","author":"IF Dingle","year":"2013","unstructured":"Dingle IF, Mishoe AE, Nguyen SA, Overton LJ, Gillespie MB. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2013;148(5):746\u201352.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"7470_CR23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clon.2006.11.005","volume":"19","author":"S Hyer","year":"2007","unstructured":"Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol. 2007;19(1):83\u20136.","journal-title":"Clin Oncol"},{"issue":"3","key":"7470_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/105072503321582060","volume":"13","author":"SJ Mandel","year":"2003","unstructured":"Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13(3):265\u201371.","journal-title":"Thyroid"},{"issue":"2","key":"7470_CR25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/CH-190717","volume":"74","author":"T Sengoz","year":"2020","unstructured":"Sengoz T, Kilic-Toprak E, Yaylali O, Kilic-Erkek O, Ozdemir Y, Oymak B, et al. Hemorheology and oxidative stress in patients with differentiated thyroid cancer following I-131 ablation\/metastasis treatment. Clin Hemorheol Microcirc. 2020;74(2):209\u201321.","journal-title":"Clin Hemorheol Microcirc"},{"issue":"8","key":"7470_CR26","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/MNM.0000000000000132","volume":"35","author":"A Fard-Esfahani","year":"2014","unstructured":"Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35(8):808\u201317.","journal-title":"Nucl Med Commun"},{"issue":"10","key":"7470_CR27","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","volume":"35","author":"M Luster","year":"2008","unstructured":"Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941\u201359.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7470_CR28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MNM.0000000000000034","volume":"35","author":"K Kulkarni","year":"2014","unstructured":"Kulkarni K, Van Nostrand D, Atkins F, Mete M, Wexler J, Wartofsky L. Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered? Nucl Med Commun. 2014;35(2):210\u20136.","journal-title":"Nucl Med Commun"},{"issue":"23","key":"7470_CR29","doi-asserted-by":"crossref","first-page":"7084-","DOI":"10.3390\/molecules26237084","volume":"26","author":"F Gorini","year":"2021","unstructured":"Gorini F, Sabatino L, Pingitore A, Vassalle C. Selenium: an element of life essential for thyroid function. Molecules. 2021;26(23):7084-.","journal-title":"Molecules"},{"issue":"3","key":"7470_CR30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41574-019-0311-6","volume":"16","author":"KH Winther","year":"2020","unstructured":"Winther KH, Rayman MP, Bonnema SJ, Heged\u00fcs L. Selenium in thyroid disorders\u2014essential knowledge for clinicians. Nat Rev Endocrinol. 2020;16(3):165\u201376.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"7470_CR31","doi-asserted-by":"crossref","first-page":"1203-","DOI":"10.3390\/nu10091203","volume":"10","author":"JC Avery","year":"2018","unstructured":"Avery JC, Hoffmann PR. Selenium, selenoproteins, and immunity. Nutrients. 2018;10(9):1203-.","journal-title":"Nutrients"},{"issue":"3","key":"7470_CR32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrendo.2011.174","volume":"8","author":"L Schomburg","year":"2012","unstructured":"Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol. 2012;8(3):160\u201371.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"7470_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s42000-020-00173-2","volume":"19","author":"ML Gheorghiu","year":"2020","unstructured":"Gheorghiu ML, Badiu C. Selenium involvement in mitochondrial function in thyroid disorders. Hormones. 2020;19(1):25\u201330.","journal-title":"Hormones"},{"issue":"8","key":"7470_CR34","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/01635581.2019.1679194","volume":"72","author":"MM de Oliveira","year":"2020","unstructured":"de Oliveira MM, Batista BAM, Sousa MP, de Souza LM, Maia CSC. Selenium and thyroid cancer: a systematic review. Nutr Cancer. 2020;72(8):1255\u201363.","journal-title":"Nutr Cancer"},{"key":"7470_CR35","doi-asserted-by":"crossref","unstructured":"O\u2019Grady TJ, Kitahara CM, DiRienzo AG, Gates MA. The association between selenium and other micronutrients and thyroid cancer incidence in the NIH-AARP Diet and Health Study. PLoS One. 2014;9(10):e110886-e.","DOI":"10.1371\/journal.pone.0110886"},{"issue":"1","key":"7470_CR36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/01635580903191569","volume":"62","author":"MA Kato","year":"2009","unstructured":"Kato MA, Finley DJ, Lubitz CC, Zhu B, Moo T-A, Loeven MR, et al. Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34. Nutr Cancer. 2009;62(1):66\u201373.","journal-title":"Nutr Cancer"},{"issue":"5","key":"7470_CR37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/thy.2006.16.455","volume":"16","author":"LH Duntas","year":"2006","unstructured":"Duntas LH. The role of selenium in thyroid autoimmunity and cancer. Thyroid. 2006;16(5):455\u201360.","journal-title":"Thyroid"},{"key":"7470_CR38","first-page":"62","volume":"20","author":"SM Lee","year":"2017","unstructured":"Lee SM, Md RGY, Lee H, Md IL, Soon Kim M, Chung WY. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer. Hell J Nucl Med. 2017;20:62\u201370.","journal-title":"Hell J Nucl Med"},{"issue":"1","key":"7470_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07315724.2001.10719007","volume":"20","author":"GN Schrauzer","year":"2001","unstructured":"Schrauzer GN. Nutritional selenium supplements: product types, quality, and safety. J Am Coll Nutr. 2001;20(1):1\u20134.","journal-title":"J Am Coll Nutr"},{"issue":"9","key":"7470_CR40","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ultrasmedbio.2021.05.013","volume":"47","author":"Z Huang","year":"2021","unstructured":"Huang Z, Chen Y, Pan L, Feng H, Wu J, Chen P, et al. Progressive changes in the major salivary gland after radioiodine therapy for differentiated thyroid cancer: a single-center retrospective ultrasound cohort study. Ultrasound Med Biol. 2021;47(9):2514\u201322.","journal-title":"Ultrasound Med Biol"},{"issue":"7","key":"7470_CR41","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/thy.2014.0525","volume":"25","author":"J-S Choi","year":"2015","unstructured":"Choi J-S, Hong SB, Hyun IY, Lim J-Y, Kim Y-M. Effects of salivary secretion stimulation on the treatment of chronic radioactive iodine-induced sialadenitis. Thyroid. 2015;25(7):839\u201345.","journal-title":"Thyroid"},{"key":"7470_CR42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nut.2017.03.007","volume":"41","author":"R Freitas","year":"2017","unstructured":"Freitas R, Nogueira RJN, Cozzolino SMF, Vasques ACJ, Hessel G. Influence of selenium supplementation on patients with inflammation: A pilot double blind randomized study. Nutrition (Burbank, Los Angeles County, Calif). 2017;41:32\u20136.","journal-title":"Nutrition (Burbank, Los Angeles County, Calif)"},{"key":"7470_CR43","doi-asserted-by":"crossref","first-page":"126653-","DOI":"10.1016\/j.jtemb.2020.126653","volume":"62","author":"E Handa","year":"2020","unstructured":"Handa E, Puspitasari IM, Abdulah R, Yamazaki C, Kameo S, Nakano T, et al. Recent advances in clinical studies of selenium supplementation in radiotherapy. J Trace Elements Med Biol. 2020;62:126653-.","journal-title":"J Trace Elements Med Biol"},{"issue":"4","key":"7470_CR44","doi-asserted-by":"crossref","first-page":"483-","DOI":"10.3390\/nu10040483","volume":"10","author":"R Muecke","year":"2018","unstructured":"Muecke R, Micke O, Schomburg L, Buentzel J, Kisters K, Adamietz IA, et al. Selenium in radiation oncology\u201415 years of experiences in Germany. Nutrients. 2018;10(4):483-.","journal-title":"Nutrients"},{"issue":"1","key":"7470_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-96637-5","volume":"11","author":"A Buczy\u0144ska","year":"2021","unstructured":"Buczy\u0144ska A, Sidorkiewicz I, Rogucki M, Siewko K, Adamska A, Ko\u015bciuszko M, et al. Oxidative stress and radioiodine treatment of differentiated thyroid cancer. Sci Rep. 2021;11(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"1","key":"7470_CR46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbrc.2019.11.047","volume":"522","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Xu T, Qin W, Huang B, Chen W, Li S, et al. Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer. Biochem Biophys Res Commun. 2020;522(1):21\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"7470_CR47","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/ERC-18-0476","volume":"26","author":"RA El Hassani","year":"2019","unstructured":"El Hassani RA, Buffet C, Leboulleux S, Dupuy C. Oxidative stress in thyroid carcinomas: biological and clinical significance. Endocr Relat Cancer. 2019;26(3):R131\u201343.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"7470_CR48","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1530\/ERC-11-0360","volume":"19","author":"M Xing","year":"2012","unstructured":"Xing M. Oxidative stress: a new risk factor for thyroid cancer. Endoc Related Cancer. 2012;19(1):C7-C.","journal-title":"Endoc Related Cancer"},{"issue":"1\u20132","key":"7470_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2006.07.017","volume":"227","author":"L Letavayov\u00e1","year":"2006","unstructured":"Letavayov\u00e1 L, Vl\u010dkov\u00e1 V, Brozmanov\u00e1 J. Selenium: from cancer prevention to DNA damage. Toxicology. 2006;227(1\u20132):1\u201314.","journal-title":"Toxicology"},{"issue":"Suppl 2","key":"7470_CR50","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.4103\/2230-8210.104090","volume":"16","author":"AK Bhuyan","year":"2012","unstructured":"Bhuyan AK, Sarma D, Saikia UK. Selenium and the thyroid: a close-knit connection. Indian J Endocrinol Metab. 2012;16(Suppl 2):S354-S.","journal-title":"Indian J Endocrinol Metab"},{"issue":"06","key":"7470_CR51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/s-0029-1220724","volume":"41","author":"LH Duntas","year":"2009","unstructured":"Duntas LH. Selenium and inflammation: underlying anti-inflammatory mechanisms. Horm Metab Res. 2009;41(06):443\u20137.","journal-title":"Horm Metab Res"},{"issue":"5","key":"7470_CR52","doi-asserted-by":"crossref","first-page":"66-","DOI":"10.3390\/antiox7050066","volume":"7","author":"E Zoidis","year":"2018","unstructured":"Zoidis E, Seremelis I, Kontopoulos N, Danezis GP. Selenium-dependent antioxidant enzymes: actions and properties of selenoproteins. Antioxidants. 2018;7(5):66-.","journal-title":"Antioxidants"},{"issue":"1","key":"7470_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-018-0504-4","volume":"18","author":"A Metere","year":"2018","unstructured":"Metere A, Frezzotti F, Graves CE, Vergine M, De Luca A, Pietraforte D, et al. A possible role for selenoprotein glutathione peroxidase (GPx1) and thioredoxin reductases (TrxR1) in thyroid cancer: our experience in thyroid surgery. Cancer Cell Int. 2018;18(1):1\u20138.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"7470_CR54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12199-007-0019-4","volume":"13","author":"U Tinggi","year":"2008","unstructured":"Tinggi U. Selenium: its role as antioxidant in human health. Environ Health Prev Med. 2008;13(2):102\u20138.","journal-title":"Environ Health Prev Med"},{"issue":"4\u20135","key":"7470_CR55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mam.2005.07.004","volume":"26","author":"P Brenneisen","year":"2005","unstructured":"Brenneisen P, Steinbrenner H, Sies H. Selenium, oxidative stress, and health aspects. Mol Aspects Med. 2005;26(4\u20135):256\u201367.","journal-title":"Mol Aspects Med"},{"issue":"7","key":"7470_CR56","doi-asserted-by":"crossref","first-page":"100111","DOI":"10.1016\/j.xcrp.2020.100111","volume":"1","author":"T Li","year":"2020","unstructured":"Li T, Xu H. Selenium-containing nanomaterials for cancer treatment. Cell Reports Physical Science. 2020;1(7):100111.","journal-title":"Cell Reports Physical Science"},{"key":"7470_CR57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10876-019-01671-z","volume":"31","author":"H Vahidi","year":"2020","unstructured":"Vahidi H, Barabadi H, Saravanan M. Emerging selenium nanoparticles to combat cancer: a systematic review. J Cluster Sci. 2020;31:301\u20139.","journal-title":"J Cluster Sci"},{"issue":"5","key":"7470_CR58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/nu13051649","volume":"13","author":"D Radomska","year":"2021","unstructured":"Radomska D, Czarnomysy R, Radomski D, Bielawska A, Bielawski K. Selenium as a bioactive micronutrient in the human diet and its cancer chemopreventive activity. Nutrients. 2021;13(5):1649.","journal-title":"Nutrients"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07470-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T18:19:47Z","timestamp":1700331587000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07470-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7470"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07470-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vice-Chancellor in Research Affairs -Medical University of Isfahan (Biomedical Research Ethics Committee) approved this project (approval code: IR.MUI.MED.REC.1400.420 on 1 September 2021). This trial is registered in the Iranian Registry of Clinical Trials (ID: IRCT20201129049534N6; registered on 16 September 2021). At baseline, (M.G) will explain the purpose of the trial to the legal guardian and will obtain their written informed consent upon registration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"This paper does not contain any personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"501"}}